Arbovirus Testing Market

Arbovirus Testing Market Outlook (2024 to 2034)

The global arbovirus testing market size is estimated at US$ 1.43 billion in 2024, according to a new Fact.MR market study. Worldwide demand for arbovirus testing is predicted to increase at a 5.7% CAGR and reach a market value of US$ 2.49 billion by the end of 2034.

The increasing prevalence of arboviral diseases, including Zika, West Nile virus, chikungunya, and dengue, among people is predicted to stimulate the demand for efficient and accurate testing methods. Constant advancements are taking place in diagnostic technologies, including ELISA (enzyme-linked immunosorbent assay), PCR (polymerase chain reaction), rapid testing kits, and nucleic acid amplification, which are contributing to more specific, sensitive, and rapid testing for arboviruses.

Funding for research, government initiatives, and public health campaigns are predicted to aim to control and prevent the spread of arbovirus diseases, which is projected to positively impact the adoption of testing technologies. Rising travel is predicted to contribute to the growing spread of arboviral infections among people across geographies, which is leading to increased demand for test kits.

Increasing awareness among the general public and healthcare professionals related to the symptoms, preventive measures, and risks associated with arboviral infections are set to propel the requirement for testing, prevention, and diagnosis.

Constant product innovations by prominent players for the development of more affordable, user-friendly, and accurate diagnostic tools are predicted to contribute to arbovirus testing market growth opportunities.

• Revenue from arbovirus testing solutions in public health laboratories is forecasted to advance at a CAGR of 5.8% and reach US$ 897.4 million by the end of 2034.
• Demand for arbovirus testing in China is predicted to increase at 6.5% CAGR and reach a value of US$ 176.8 million by 2034-end.
• Public health laboratories are projected to account for 36.1% share of global market revenue by 2034.

Several stringent guidelines and regulations by health authorities about the safety, quality, and efficacy of arbovirus diagnostic tools are predicted to positively impact market dynamics and growth.

Report Attributes	Details
Arbovirus Testing Market Size (2024E)	US$ 1.43 Billion
Forecasted Market Value (2034F)	US$ 2.49 Billion
Global Market Growth Rate (2024 to 2034)	5.7% CAGR
North America Market Share(2034F)	18.1%
Demand Growth in Japan (2024 to 2034)	5.2% CAGR
United States Market Value (2034F)	US$ 286 Million
Arbovirus Testing in Public Health Laboratories Segment Value (2024E)	US$ 897.4 Million
ELISA-based Test Segment Share (2034F)	59.2%
Key Companies Profiled	Agilent Technologies Inc. NovaTec Immundiagnostica GmbH Thermo Fisher Scientific Euroeimmun AG Abbot Laboratories Bio-Rad DiaSorin SpA Fluke Biomedical Distek Copley Scientific Becton Distek Dickinson and Company Hoffmann La Roche Ltd. Merck kGaA F QIAGEN N.V. Siemens Healthineers AG

What is Contributing to the Expanding Arbovirus Testing Market Size?

“Rising Cases of Arboviral Infections Prompting More Research Efforts across the World”

There has been an unprecedented increase in the cases of arboviral diseases over the past few years. Conventionally, these diseases are associated with certain climates or regions. These cases are also found in new geographical areas owing to several factors, including increased travel, climate change, etc.

Dengue was once confined to subtropical and tropical regions, currently, its cases are also found in other regions as well. Arbovirus infections pose challenges to public health owing to their potential to cause epidemics and outbreaks. Several diseases, including Zika, dengue, and chikungunya, are expected to lead to severe symptoms, including rashes, neurological complications, joint pain, high fever, and even fatalities.

Rising cases of arbovirus infections are predicted to spur research efforts for a better understanding of the epidemiology, pathogenesis, and transmission dynamics of these diseases. These R&D activities are anticipated to contribute to the development of more effective and better diagnostic tools, along with creating awareness about their surveillance, prevention, and control.

“Government Initiatives and Funding Stimulating Adoption of Testing Technologies”

Most governments recognize arbovirus diseases as a pivotal health concern owing to their potential to cause public health emergencies, severe illness, and outbreaks. Consequently, more governments generally prioritize these healthcare issues in their health agendas, providing funding, allocating resources, and establishing programs, aimed at surveillance, control, and prevention.

More governments are entering into collaboration with research institutions and public health agencies to provide funding for R&D activities related to arbovirus infection. They aim to support scientific investigations into several aspects of arboviral diseases, including pathogenesis, vaccine development, diagnostics, and epidemiology. Financial support and research grants facilitate the development of novel testing technologies, protocols, and tools for the diagnosis of arboviral infections rapidly and accurately.

What Can Adversely Impact Arbovirus Testing Market Growth?

“Lack of Awareness and Limited Access to Diagnostic Testing Techniques”

There is a lack of awareness about the facilities available for arbovirus infections among people in developing countries. In addition, limited access to these advanced diagnostic procedures in developing countries is predicted to reduce their adoption.

How are Start-ups Establishing Themselves in This Competitive Market?

“Focus on Exploration of Innovative Testing Methodologies”

There is always room for innovations in testing methodologies. The development of more economical, rapid, and accurate diagnostic tools against arbovirus infections is predicted to widen the scope for new entrants. Some of the advancements include point-of-testing, molecular diagnostics, and novel platforms, which can enhance specificity and sensitivity.

Country-wise Insights

As per fact.MR report, North America is projected to hold 18.1% share of global market revenue by 2034. This is attributed to the increased adoption of several technologically advanced products and increased healthcare expenditure.

Why is the United States a Key Market for Arbovirus Testing Solutions?

“Availability of Sophisticated Diagnostic Tests in the Country”

Attribute	United States
Market Value (2024E)	US$ 190.9 Million
Growth Rate (2024 to 2034)	4.1% CAGR
Projected Value (2034F)	US$ 286 Million

The United States is predicted to hold a 63.4% share of the North American market by 2034. The market in the United States is predicted to hold a significant share of the regional market because of the rising prevalence of arbovirus infection. In addition, the growing availability of point-of-care molecular diagnostics in clinical facilities is also widening their application scope. Moreover, the presence of a well-established healthcare infrastructure and increased healthcare spending are also predicted to positively impact market growth opportunities.

The rising population of elderly people, who are susceptible to viral infections, is also predicted to accelerate demand for testing facilities. Furthermore, the development of integrated response strategies to reduce arbovirus cases is also contributing to revenue streams.

How Fast is Demand for Arbovirus Testing Rising in China?

“Larger Population Density Leading to More Cases of Arboviral Infections”

Attribute	China
Market Value (2024E)	US$ 94.2 Million
Growth Rate (2024 to 2034)	6.5% CAGR
Projected Value (2034F)	US$ 176.8 Million

China is forecasted to account for 46.7% share of the East Asia market by 2034. The larger population in China is predicted to lead to a wider spread of arboviral diseases. Therefore, requirements for effective testing solutions are experienced by patients and healthcare providers, which are predicted to widen the scope for players there.

Category-wise Insights

According to the study published by Fact.MR, a market research and competitive intelligence provider, public health laboratories are predicted to adopt arbovirus testing services extensively to promote knowledge sharing, improve testing accuracy, and standardize testing protocols.

Why is There Higher Adoption of ELISA-based Tests?

“Easy Availability and Accessibility of ELISA-based Tests”

Attribute	ELISA-based Tests
Segment Value (2024E)	US$ 850.4 Million
Growth Rate (2024 to 2034)	5.6% CAGR
Projected Value (2034F)	US$ 1.47 Billion

ELISA-based tests are projected to hold a 59.2% share of global market revenue by 2034. ELISA-based tests are used for the assessment of the effectiveness of control measures, guiding targeted interventions, and identifying areas with higher risks that are forecasted to contribute to segment growth. In addition, the easy accessibility and accuracy of ELISA-based tests are attracting arbovirus testing market trends.

Increased demand for ELISA-based tests is also attributed to a growing focus on R&D activities along with technological advancements to detect arbovirus disorders. Several innovations along with constant improvements in assay sensitivity, design, and specificity for improved diagnostic effectiveness and pocket-friendly prices, are predicted to offer noteworthy growth potential.

Which End User Accounts for Widespread Use of Arbovirus Testing Solutions?

“Extensive Adoption of Arbovirus Testing by Public Health Laboratories”

Attribute	Public Health Laboratories
Segment Value (2024E)	US$ 510.8 Million
Growth Rate (2024 to 2034)	5.8% CAGR
Projected Value (2034F)	US$ 897.4 Million

Public health laboratories are projected to hold 36.1% arbovirus testing market share by 2034. An increasing number of public health laboratories is predicted to lead to extensive adoption of several advanced diagnostic techniques for arbovirus testing, including high-throughput platforms and rapid molecular assays to enable more accurate and faster arbovirus detection.

Several public health laboratories are entering into collaborations with public health agencies, diagnostic companies, and research institutions to expand their facilities in testing services. In addition, they also promote standardization of testing protocols and knowledge sharing and invest in novel technology development, which is predicted to lead to improved efficiency and accuracy in testing procedures.

Competitive Landscape

Prominent suppliers of arbovirus testing tools are adopting several strategies to achieve set purposes, including management of supply chain systems, ensuring quality control of products, and innovations. Companies are implementing several growth strategies, including product launches and collaborations, to gain a competitive edge.

For instance :

• Mylab, in July 2022, launched the PathoDetect Extended Monsoon Fever Panel. This newly developed RT-PCR test kit works more effectively for monsoon disorders, including dengue, malaria, and Zika. This newly developed kit offers accurate results in two hours along with a mass testing feature.

Key players in the arbovirus testing industry are Agilent Technologies Inc., NovaTec Immundiagnostica GmbH, Thermo Fisher Scientific, Euroeimmun AG, Abbot Laboratories, Bio-Rad, DiaSorin SpA, Fluke Biomedical, Distek, Copley Scientific, Becton, Distek, Dickinson and Company, Hoffmann La Roche Ltd., Merck kGaA F, QIAGEN N.V., and Siemens Healthineers AG.

Segmentation of Arbovirus Testing Market Research

• By Test Type :

  • ELISA-based Tests
  • RT-PCR Tests

• By End User :

  • Hospitals
  • Public Health Laboratories
  • Diagnostic Centers

• By Region :

  • North America
  • Europe
  • East Asia
  • Latin America
  • Middle East & Africa
  • South Asia & Oceania